Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
Compass Therapeutics (CMPX) Stock Price & Analysis
183 Followers
CMPX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.15 - $3.62
Previous Close$1.6
Volume70.10K
Average Volume (3M)353.20K
Market Cap
$220.14M
Enterprise Value$69.41M
Total Cash (Recent Filing)$152.46M
Total Debt (Recent Filing)$1.73M
Price to Earnings (P/E)-4.6
Beta1.13
Next Earnings
Jul 31, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding137,589,171
10 Day Avg. Volume285,107
30 Day Avg. Volume353,196
Standard Deviation0.27
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$9.00Price Target Upside466.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Compass Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPromising preclinical data presented at AACR for combination therapy with CTX-009 and CTX-471 shows the potential for a new treatment strategy in tumor models resistant to current therapies.
Financial PositionThe company's strong financial position with significant cash reserves is expected to support ongoing operations and clinical trials well into the future, providing assurance to investors about the company's stability.
Regulatory AdvancementsCTX-009 + paclitaxel was recently awarded FDA fast track designation in 2L+ biliary tract cancer, highlighting the therapy's potential for expedited review and patient access.
Bears Say
Clinical Trial ResultsCurrent treatment outcomes in 3L CRC show poor survival rates, with a 7-month median overall survival.
Drug EfficacyAn objective response rate (ORR) below 10% will likely not meet the internal efficacy threshold for pursuing a monotherapy opportunity, indicating a possible setback if results do not meet expectations.
Stock ValuationThe net of changes lowers price target to $10.
---
Ownership Overview
35.66% Insiders
6.00% Mutual Funds
52.95% Other Institutional Investors
5.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $1.15 and its highest was $3.62 in the past 12 months.
What is Compass Therapeutics’s market cap?
Currently, no data Available
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is Jul 31, 2024 which is in 72 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on May 06, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.033.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -$0.1.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 137,589,170 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Among the largest hedge funds holding Compass Therapeutics’s share is Blackstone Inc.. It holds Compass Therapeutics’s shares valued at 12M.
---
Compass Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (466.04% Upside)
$9.00 (466.04% Upside)
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.0%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.61%
12-Months-Change
Fundamentals
Return on Equity
-27.35%
Trailing 12-Months
Asset Growth
-14.27%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.
---
CMPX Stock 12 Month Forecast
Average Price Target
$9.00
▲(466.04% Upside)
Technical Analysis
Best Analysts Covering CMPX
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+9.82%
reiterated a buy rating 8 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +9.82% per trade.
---